# The Lilly and Hims access agreement Canonical: https://europeanpeptideshop.com/blog/lilly-hims-zepbound-foundayo-access-agreement/ Explore the catalogue and research library. Ordering and shipping have not opened yet. Research news · 8 November 2026 · 3 min read · By [European Peptide Shop](https://europeanpeptideshop.com/about/) ### On this page Lilly and Hims & Hers announced an agreement on November 6, 2026 that lets eligible patients prescribed Zepbound or Foundayo access Lilly’s self-pay prices within the Hims & Hers platform. The announcement concerns access to branded medicines. [1](https://news.hims.com/newsroom/lilly-and-hims-hers-expand-access-to-fda-approved-lilly-medicines) ## What does the agreement change? The companies describe consultation, prescribing when appropriate and delivery within one platform experience. The agreement does not make a prescription automatic: the provider decides whether a medicine is suitable. The release also states that independent clinical decision-making will be preserved. [1](https://news.hims.com/newsroom/lilly-and-hims-hers-expand-access-to-fda-approved-lilly-medicines) The reading is that the useful news question is how the access arrangement works. A distribution agreement alone does not establish that a medicine works better, that every applicant qualifies or that the platform is the best option for an individual. [1](https://news.hims.com/newsroom/lilly-and-hims-hers-expand-access-to-fda-approved-lilly-medicines) ## What do the advertised prices cover? The release advertises self-pay starting prices of $149 per month for Foundayo and $299 for Zepbound. Those are starting figures, not a verified all-inclusive quote for every formulation, treatment stage or membership arrangement. This report did not test a checkout or obtain a patient-specific quote. [1](https://news.hims.com/newsroom/lilly-and-hims-hers-expand-access-to-fda-approved-lilly-medicines) ## Are Zepbound and Foundayo the same kind of molecule? Foundayo contains orforglipron, which FDA describes as a non-peptide GLP-1 receptor agonist. It is an oral small molecule. Zepbound contains tirzepatide and is an injectable medicine. Sharing a connection to GLP-1 signaling does not make the products chemically identical or interchangeable. [2](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/220934Orig1s000MultidisciplineR.pdf) [3](https://investor.lilly.com/news-releases/news-release-details/FDA-approves-lillys-foundayotm-orforglipron-only-GLP-1-pill) FDA’s Foundayo review distinguishes the tablet formulation from the capsules used in its Phase 3 program and discusses the evidence connecting them. That illustrates why a drug name, molecular mechanism and finished formulation each matter when reading clinical claims. An oral GLP-1 headline does not always mean an oral peptide. [2](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/220934Orig1s000MultidisciplineR.pdf) ## How is this different from Hims Peptides+? Hims’ October 29 Peptides+ announcement previewed a different specialty and invited people to join a launch list. Its proposed offerings included several therapies, with BPC-157 and TB-500 described as conditional future additions. That announcement should not be merged with the November branded-medicine agreement. [4](https://news.hims.com/newsroom/expanding-safe-access-to-peptides) The two stories answer different questions: the earlier preview describes a planned service, while the Lilly announcement describes an agreement involving named FDA-approved medicines. Neither statement establishes that every therapy discussed across the company’s announcements is available on the same terms. [1](https://news.hims.com/newsroom/lilly-and-hims-hers-expand-access-to-fda-approved-lilly-medicines) [4](https://news.hims.com/newsroom/expanding-safe-access-to-peptides) ## Does platform access establish FDA approval? FDA distinguishes compounded preparations from approved medicines and approved generics. A compounded product does not acquire approval merely because an approved drug contains the same active ingredient. The regulatory status belongs to the particular product and approval pathway, not to the platform carrying its name. [5](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers) ## Scope for European readers This is a dated account of the research or policy described in the linked sources. The stated jurisdiction, study product and population matter. A US or UK announcement does not establish authorisation or availability across Europe. Nothing in this report establishes results for an EPS catalogue material. Read the [research-use statement](https://europeanpeptideshop.com/research-use/) for the storefront's scope. ## Laboratory research only Materials listed on this site are supplied for in-vitro laboratory research and are not for use in or on humans or animals. They are not medicines. This article summarises published work and gives no dosing, administration, treatment or in-vivo guidance. Findings from a study apply to the material and conditions of that study, and they say nothing about any product listed here. ## References - [Hims & Hers and Lilly: joint access announcement, November 6, 2026](https://news.hims.com/newsroom/lilly-and-hims-hers-expand-access-to-fda-approved-lilly-medicines) - [FDA: Foundayo multidisciplinary review, NDA 220934](https://www.accessdata.fda.gov/drugsatfda_docs/nda/2026/220934Orig1s000MultidisciplineR.pdf) - [Lilly: Foundayo approval announcement](https://investor.lilly.com/news-releases/news-release-details/FDA-approves-lillys-foundayotm-orforglipron-only-GLP-1-pill) - [Hims & Hers: Peptides+ preview, October 29, 2026](https://news.hims.com/newsroom/expanding-safe-access-to-peptides) - [FDA: Compounding and the FDA, questions and answers](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers) ## More articles Research news · 3 min read ## [What Hims announced for Peptides+](https://europeanpeptideshop.com/blog/hims-peptides-plus-announcement/) What Hims & Hers announced about Peptides+ on October 29, 2026, which therapies remain planned, and how pharmacy access differs from FDA approval. 8 November 2026 Research news · 2 min read ## [Australia's Synedica peptide warning](https://europeanpeptideshop.com/blog/synedica-tga-warning-australia-tb-500/) Australian testing found Synedica peptide products contained no TB-500 and less retatrutide than labelled. The TGA has told Australians to discard them. 8 November 2026 Research news · 3 min read ## [Avexitide and the LUCIDITY trial](https://europeanpeptideshop.com/blog/avexitide-glp-1-antagonist-lucidity/) Why does avexitide block GLP-1? Explore post-bariatric hypoglycemia, LUCIDITY results and Amylyx’s November 2026 FDA-filing and conference plans. 8 November 2026